Savient Pharmaceuticals is a specialty biopharmaceutical company whose mission is to develop and commercialize pharmaceutical specialty products. The company announced today that it and Swedish Orphan Biovitrum AB (SOBI) have entered into an agreement for the co-promotion of Kineret (anakinra) in the United States.
Sobi, an international specialty healthcare company dedicated to treatments for rare diseases, has a product portfolio primarily focused on inflammation and genetic diseases, with three late-stage biological development projects. Additionally, the company markets a portfolio of specialty and rare products with overseas partners such as Savient.
Kineret, a recombinant IL-1 receptor antagonist, is a treatment for rheumatoid arthritis (RA) and indicated for the reduction in symptoms and slowing the progression of structural damage in patients with moderately to severely active RA. These patients, ages 18 or older, have failed one or more disease modifying anti-rheumatic drugs (DMARDs). Keneret is also indicated in the U.S. for the treatment of children and adults with the severe form of Cyropyrin-Associated Periodic Syndromes (CAPS) called Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
Under the terms of the agreement, Sobi granted to Savient the exclusive right to co-promote the sale of Kineret in the U.S. Savient will market and promote the drug beginning on April 1, 2013. Sobi remains responsible for all Kineret commercial drug manufacturing, supply, safety, and regulatory activities. This collaboration will expand Savient’s existing relationships with rheumatologists and patients with rheumatoid arthritis.
For additional information on Savient Pharmaceuticals, visit www.savient.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
